Checkpoint Therapeutics, Inc.
(NASDAQ : CKPT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.05%42.410.9%$1154.22m
JNJJohnson & Johnson
1.54%136.380.6%$1031.22m
MRKMerck & Co., Inc.
1.14%79.840.6%$980.94m
LLYEli Lilly and Company
1.41%122.451.0%$890.74m
BMYBristol-Myers Squibb Company
1.59%51.641.4%$801.53m
ABBVAbbVie, Inc.
0.40%80.842.2%$633.73m
AZNAstraZeneca PLC Sponsored ADR
2.35%40.921.3%$202.14m
NVSNovartis AG Sponsored ADR
0.98%89.890.2%$197.85m
GSKGlaxoSmithKline plc Sponsored ADR
0.93%41.240.2%$146.59m
NVONovo Nordisk A/S Sponsored ADR Class B
1.15%50.350.1%$73.10m
SNYSanofi Sponsored ADR
2.38%42.550.2%$37.68m
LCILannett Company, Inc.
4.92%9.8137.0%$16.02m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.11%1.851.7%$0.05m
EPIXESSA Pharma Inc
3.88%3.750.1%$0.05m

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX). It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP). The company was founded on November 10, 2014 and is headquartered in New York, NY.